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ABSTRACT
Background. In postmenopausal women diagnosed with breast
cancer (BC), most BC tumors are hormone receptor positive and
guidelines recommend adjuvant endocrine therapy that includes
an aromatase inhibitor (AI). This study investigates the impact of a
6-week, home-based, self-directed walking program on the com-
monly reported side effect of AI-associated arthralgia (AIAA).
Materials and Methods. In this phase II trial, consented BC
patients were randomized to walking Intervention (n5 31) or
Wait List Control (WLC; n5 31). Eligibility criteria included:
stage 0–III BC, on AI for at least 4 weeks, 3 on a 5-point scale
inquiring about joint symptom intensity “at its worst,” and exer-
cising 150 minutes per week. Outcomes were self-reported
joint symptoms and psychosocial measures. Analyses compar-
ing Intervention and WLC groups were conducted on an
intention-to-treat basis to assess intervention impact at 6
weeks (postintervention) and at 6-months follow-up. Adjusted
means were calculated to assess differences in two groups.
Results. In our final sample (n5 62), mean age was 64 years,
74% were white, and 63% had a body mass index of 30 or
higher. At postintervention, Intervention group participants
reported significantly increased walking minutes per week,
reduced stiffness, less difficulty with activities of daily living
(ADL), and less perceived helplessness in managing joint symp-
toms. At 6-months follow-up (postwalking period in both Inter-
vention and WLC), walking minutes per week had decreased
significantly; however, improvements in stiffness and difficulty
with ADLs were maintained.
Conclusion. This study adds to the growing evidence base sug-
gesting exercise as a safe alternative or adjunct to medications for
the management of AIAA. The Oncologist 2017;22:1238–1248
Implications for Practice: Breast cancer survivors whose adjuvant endocrine treatment includes an aromatase inhibitor (AI) often
experience the side effect of AI-associated arthralgia (AIAA). This study investigates the impact of a 6-week, home-based, self-
directed walking program in the management of AIAA. Compared withWait List Control, women in the Intervention group reported
significantly increased walking minutes per week, reduced stiffness, less difficulty with activities of daily living, and less perceived
helplessness in managing joint symptoms. This study adds to the growing evidence base suggesting exercise as a safe alternative or
adjunct to medications for the management of AIAA.
INTRODUCTION
Most new cases of breast cancer are diagnosed in postmeno-
pausal women, and in 70%–80% of these women, their tumors
are hormone receptor positive (HR1), for which national guide-
lines recommend adjuvant endocrine therapy that includes an
aromatase inhibitor (AI) [1, 2]. Joint symptoms of pain, stiffness,
and achiness (arthralgia) are commonly reported side effects of
AI treatment, affecting an estimated 33%–74% of breast cancer
patients on AI therapy seen in clinical practice, and rated mod-
erate to severe by as many as 70% of women who report them
[3, 4]. For most breast cancer survivors experiencing AI-
associated arthralgia (AIAA), pharmacological remedies such as
analgesics and antidepressants provide little or no joint symp-
tom relief [6]. There is a need to identify effective, easy-to-use,
sustainable, and safe alternative or adjunctive approaches to
AIAA management, so that they are able to remain on AI ther-
apy while having as pain-free a life as possible.
We investigated whether an evidence-based walking pro-
gram developed by Callahan and colleagues, which is effective
Correspondence: Kirsten A. Nyrop, Ph.D., Division of Hematology-Oncology, School of Medicine, University of North Carolina at Chapel Hill, CB
7305, Chapel Hill, North Carolina 27599, USA. Telephone: 919-962-6735; e-mail: kirsten_nyrop@med.unc.edu Received April 20, 2017; accepted
for publication June 12, 2017; published Online First on July 26, 2017. http://dx.doi.org/10.1634/theoncologist.2017-0174
TheOncologist 2017;22:1238–1248 www.TheOncologist.com Oc AlphaMed Press 2017
Breast Cancer
in reducing joint symptoms in adults with arthritis (Arthritis
Foundation’s Walk With Ease [WWE]) [7], could have similar
benefits for women experiencing AIAA.We have reported else-
where about our adaptation of the WWE program for breast
cancer survivors on AI therapy through interviews and pilot
testing (WWE-Breast Cancer [WWE-BC]) [8–10]. Here, we pres-
ent findings from a 6-week randomized phase II “proof of con-
cept” study designed to evaluate the effect of WWE-BC
between baseline and 6 weeks (end of intervention) and at
6-months follow-up. The specific focus of our study is breast
cancer survivors reporting moderate to severe AIAA. Primary
outcomes were patient-reported and included the following:
(a) engagement in walking (minutes per week), (b) joint pain/
symptoms, and (c) adherence to AI therapy. Secondary out-
comes were as follows: (a) self-efficacy to engage in physical
activity and manage joint pain/symptoms, (b) psychosocial
measures of quality of life, and (c) satisfaction with WWE-BC.
We also report feasibility (recruitment), tolerability (retention),
and safety (adverse events).
MATERIALS AND METHODS
Participants
The study sample was identified through a review of the
appointment schedule for women being seen in breast cancer
clinics at a university-affiliated tertiary care hospital. The
recruitment period was February 2014 through August 2015.
Oncology providers of patients identified as potential study
participants were approached to ascertain the patient’s appro-
priateness for the intervention study and current status of AI
treatment compliance. To be eligible for the study, patients had
to be adherent to their AI prescription for at least 4 weeks, age
21 or older, and not undergoing chemotherapy or radiation
treatment during the study period. Patients approved by their
provider were then screened in person by study staff. To iden-
tify patients with moderate to severe AIAA, eligibility was lim-
ited to patients who scored 3 or higher on a 5-point scale
inquiring about joint pain, stiffness, or achiness intensity “at its
worst” in the past 7 days (PROMIS Pain Intensity—Short Form
3a) [11]. Patients were also asked how many days a week they
engaged in physical activity for exercise or pleasure and how
many minutes per day they did so. For study eligibility, patients
had to be exercising below the guideline-recommended level
of 150 minutes per week [12]. Patients who met both pain and
physical activity criteria were then invited to review informed
consent forms and provide written consent to participate in the
study. The intervention study protocol was approved by the
UNC Lineberger Comprehensive Cancer Center Protocol Review
Committee and the UNC Institutional Review Board. The study
was registered with clinicaltrials.gov (NCT01900418).
Intervention
Walk With Ease-Breast Cancer has been described in detail
elsewhere [8, 9]. The evidence base for WWE was established
in group-based classes and as a self-directed physical activity
program for adults with arthritis [7]. Walk With Ease includes a
WWE workbook that encourages participants to walk for at
least 150 minutes per week. For our phase II proof of concept
study, consented patients were randomized to Intervention or
Wait List Control (WLC).
The intervention period was 6 weeks (as tested in the origi-
nal WWE study [7]), during which study participants were
asked to walk on their own or with others at a pace that
was safe, comfortable, and sustainable at the guideline-
recommended level of 150 minutes per week. Participants
received a copy of the Arthritis Foundation’s Walk With Ease
workbook [13] with strategies for starting and sustaining a daily
walking program. Participants also received a 4-page brochure
developed by the research team titled “Walk With Ease for
women with a breast cancer diagnosis” containing brief topics
such as “Why walk,” “Joint pain and some cancer treatments,”
quotes from women who had completed the walking program
in a prior pilot study [8], “How to get started,” and a summary
of the “UNC Pilot Study.” In addition, participants received a
printed physical activity log to record daily minutes of walking
for leisure, pleasure or recreation. There was no contact with
study participants during the 6-week intervention period. The
WLC group was asked to await further contact from the
research team at 6 weeks after study enrollment/baseline, at
which time they received the same materials and instructions
as the Intervention group and were encouraged to walk 150
minutes per week.
Questionnaires
At baseline, consented patients received a printed question-
naire with a self-addressed stamped return envelope and were
asked to mail in the completed questionnaire within 1 week of
recruitment. Up to three email and telephone follow-ups were
conducted weekly to encourage baseline retention in the study
through the completion of the baseline questionnaire. At
6 weeks from baseline, the Intervention group was mailed a
6-week questionnaire with a self-addressed stamped envelope
for returning the questionnaire. The questionnaire included
“Program Satisfaction” questions and a request to include their
walking diary in the return envelope. At this 6-week time point,
WLC participants were also mailed the 6-week questionnaire,
but without the satisfaction questions. At that time, the WLC
participants were provided instructions and materials and
encouraged to start the walking program. Six weeks later, the
WLC group received a second 6-week questionnaire that
included the satisfaction questions and a request to return the
walking diary in the self-addressed stamped envelope provided
by the study team. Both Intervention and WLC groups were
mailed a 6-months follow-up questionnaire, 6 months after
they had completed the walking program.
Measures
Measures included in the questionnaires are summarized in
Table 1. All measures pertain to patient-reported outcomes
and are validated and commonly used in cancer or rheumatol-
ogy research. Self-reported symptom measures included (a)
separate Visual Analog Scales (VAS) for pain, stiffness, and
fatigue [14] and (b) Western Ontario and McMaster Univer-
sities Osteoarthritis Index (WOMAC) [15] subscales for pain,
stiffness, and function/difficulties with activities of daily living.
Psychosocial measures included (a) Functional Assessment of
Cancer Therapy-General (FACT-G) [16] subscales for physical,
social/family, functional and emotional well-being and (b)
Rheumatology Attitudes Index (RAI) [17], a measure of per-
ceived control over rheumatology symptoms. Efficacy for pain
self-management was measured using the Arthritis Self-Efficacy
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Scale (ASE) subscales for pain and symptoms [18]. Additional
psychosocial measures pertained to efficacy and outcome
expectations for physical activity: Outcome Expectations from
Exercise [19] and Self-Efficacy for Physical Activity [20] scales.
Study participants were also asked to provide demographic
information (age, race, ethnicity, education, marital status,
height, weight), self-assessed general health (15 excellent to
55 poor), and breast cancer stage and treatment. With regard
to AI adherence during the study period, the study participants
were asked to report how often they (a) forgot to take their AI
therapy as prescribed and (b) chose not to take the AI therapy
as prescribed, with response options from 15 never forgot/
never chose not to take the AI to 55 very often forgot/often
chose not to take the AI as prescribed. Participants were
queried about physical activity through the following items: (a)
How many days a week do you go for a walk for at least 10
minutes, for any reason, in and around your neighborhood
or elsewhere? and (b) Howmuch time (minutes) do you usually
spend when you go for a walk in and around your
neighborhood or elsewhere? Responses to both questions
were multiplied to ascertain total minutes of walking per week.
Statistical Analysis
Analyses were conducted on an intention-to-treat (ITT) basis.
During recruitment, three participants who were randomized to
receive the intervention were inadvertently assigned to the
WLC group instead, and three others who were randomized to
the WLC group were inadvertently assigned to receive the inter-
vention. One of the mis-randomized WLC participants did not
complete the 6-week follow-up questionnaire, leaving 5 mis-
randomized study participants. The mis-randomizations were
unintentional and were found to be non-differential when com-
paring baseline demographic characteristics with those who
were correctly randomized. Further, the mis-randomized partici-
pants still received a protocol-defined regimen (the walking
intervention). We therefore decided to go forward with the ITT
analyses, with all participants analyzed according to the group
Table 1. Measures
Domain Explanation
Self-reported walking
Walking (on average)
. . . days per week
. . . minutes per day
Days times minutes/day5minutes/week
Self-reported joint symptoms
VAS
Pain: how much pain/achiness/discomfort
have you had in and around your joints
over the past week?
Stiffness: How much of a problem has
stiffness been for you over the past week?
Fatigue: How much of a problem has unusual
fatigue or tiredness been for you over
the past week?
05 no pain to 105 pain as bad as it could be.
Score 4 is associated with premature AI discontinuation [29].
05 no stiffness to 105 stiffness as bad as it could be.
05 fatigue is no problem to 105 fatigue is a major problem.
Severe fatigue is defined as 4 [30].
WOMAC
Pain subscale
Stiffness subscale
Function/difficulties with activities of daily living
Higher score5 greater pain, range 0–20
Higher score5 greater stiffness, range 0–8
Higher score5 greater difficulties, range 0–68
Total joint pain locations on a body chart Range 1–10 locations
Psychosocial measures
FACT-G
Physical well-being
Social/family well-being
Functional well-being
Emotional well-being
Lower score5 greater symptoms, range 0–28
Lower score5 less support, range 0–28
Lower score5 lower function, range 0–28
Lower score5more emotional concerns, range 0–24
RAI Higher score5 greater perceived helplessness
Range 1–5
Efficacy for pain self-management
ASE
Pain
Symptoms
Lower score5 lower self-efficacy
Range 1–10
Range 1–10
Efficacy and outcome expectations for physical activity
OEE Higher score5 negative outcome expectations
Range 1–5
SEPA Higher score5 higher confidence in being physically active
Range 1–5
Abbreviations: ASE, arthritis self-efficacy scale; FACT-G, functional assessment of cancer therapy-general; OEE, outcome expectations from exercise;
RAI, rheumatology attitudes index; SEPA, self-efficacy for physical activity; VAS, visual analog scale; WOMAC, Western Ontario and McMaster
Universities osteoarthritis index.
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to which they were assigned regardless of the inadvertent ran-
domization errors.
Baseline descriptive statistics were computed for partici-
pant demographic characteristics, joint symptom, psychosocial
and efficacy measures, and other items inquiring about breast
cancer diagnosis and treatments, AI adherence, self-reported
health, and physical activity using means with standard devia-
tion (SD) for continuous variables and percentages for categori-
cal variables. Independent chi-square tests and Student’s t tests
were used to compare categorical and continuous participant
characteristics, respectively.
For longitudinal analyses, least squares mean estimates
were calculated with 95% confidence intervals at baseline and
6-week follow-up for the Intervention and WLC groups sepa-
rately. Differences in mean psychosocial responses from the
baseline to the 6-weeks follow-up were then compared
between two groups. Adjusted means were calculated for the
primary and secondary outcomes at baseline, postintervention
follow-up (6 weeks), and at the end of the study (6-months fol-
low-up) for the total sample and the differences between the
end of intervention (6 weeks for Intervention group and 12
weeks for WLC group) and 6-months follow-up in both groups.
Covariates included age, race, education, body mass index
(BMI; kg/m2), and breast cancer stage. We used mixed models
to account for any autocorrelation within individual study
participants.
As estimates for a future power calculation for larger sam-
ple randomized controlled trials, we calculated effect size
expressed as Cohen’s d [21] as the difference between the
mean change scores from baseline to 6 weeks for the Interven-
tion and WLC groups divided by the pooled baseline SD with
adjustment for small sample size [22]. To interpret effect sizes,
we used Cohen’s “rules of thumb”: small5 0.20, medium-
5 0.50, and large5 0.80 [21].
As a proof of concept study, statistical significance was not
our highest priority. However, we calculated a priori that a sample
size of 60 participants would have an 80% power to detect an
effect size of 0.37 or greater for the measures of VAS pain, stiff-
ness, and fatigue. In the parent WWE study [7], our observed
effect sizes for self-directed participants were 0.36, 0.40, and 0.21,
respectively. All analyses were conducted using SAS 9.4 (SAS Insti-
tute, Cary, NC, https://www.sas.com/en_us/home.html).
RESULTS
Recruitment, Retention, and Safety
The total number of patients identified for screening was 416
(Fig. 1); this figure does not include multiple contacts with
Number of unique (non-duplicate)* patients 
identified for screening in clinic 
n = 416 
Not screened at oncology provider’s request 
n = 54 (13% of 416) 
(disease advancement, other medical complexities, psychosocial 
issues, etc.) 
Unique (non-duplicate)* patients  
screened in clinic by research staff 
n = 362 (87% of 416) 
Patients who declined to participate in the study 
n = 18 (5% of 362) 
Unique (non-duplicate)* patients  
screened for the study 
n = 344 (95% of 362) 
Patients determined ineligible for the study 
n = 266 (77% of 344) 
Reasons for ineligibility 
n = 98     no/low pain (37% of 267) 
n = 145   both too active and no/low pain (55% of 267) 
n = 15     too active but high pain (6% of 267) 
n = 8       too active, unclear pain level (3% of 267) 
Eligible and consented to the study 
n = 78 (23% of 344) 
Did not complete the baseline questionnaire 
n = 16 (21% of 78) 
Reasons for not completing the baseline questionnaire 
n = 1     breast cancer progression 
n = 4     psychosocial 
n = 11   no longer interested, no reason 
All baseline requirements completed 
n = 62 (79% of 78)  
n = 31 Intervention, n = 31 WLC 
Did not complete the 6-week questionnaire 
n = 9 
Completed the 6-week questionnaire 
n = 53 (85% of 62) 
n = 24 Intervention (77%), n = 29 WLC (94%) 
(n = 24 of WLC completed second 6-week = 83%) 
Completed the 6-month questionnaire 
n = 41 (77% of 53) 
Figure 1. STROBE. *, Unique patients were screened 2–3 times to see if their joint symptoms or physical activity level had changed over time.
Abbreviation: WLC, wait list control.
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Table 2. Baseline characteristics of Intervention and Wait List Control groups
Characteristic
Total
n (%)
Intervention
n (%)
Wait List Control
n (%) p valuea
Demographics
Age at baseline, years 63.86 8.3 63.36 6.9 64.46 9.7 .59
Education, high school 14 (23%) 6 (19%) 8 (27%) .46
Body mass index, 30 kg/m2 7 (11%) 3 (9%) 4 (13%) .95
White race 46 (74%) 23 (72%) 23 (77%) .67
General health .15
Excellent 2 (3%) 2 (7%) 0 (0%)
Very good 16 (27%) 6 (19%) 10 (35%)
Good 32 (53%) 16 (52%) 16 (55%)
Good-to-fair 1 (2%) 0 (0%) 1 (3%)
Fair 9 (15%) 7 (23%) 2 (7%)
Breast cancer clinical characteristics
Breast cancer stage .42
I 25 (40%) 10 (31%) 15 (50%)
II 20 (32%) 11 (34%) 9 (30%)
III 7 (11%) 5 (16%) 2 (7%)
IV 10 (16%) 6 (19%) 4 (13%)
Total years after diagnosis 2.86 2.5 2.76 2.9 2.86 2 .91
Radiation 43 (74%) 21 (70%) 22 (79%) .46
Chemotherapy 35 (65%) 18 (62%) 17 (68%) .65
Lumpectomy 31 (84%) 13 (72%) 18 (95%) .06
Mastectomy 24 (57%) 11 (52%) 13 (62%) .53
Ever taken tamoxifen 16 (29%) 11 (41%) 5 (17%) .05
Currently taking exemestane 12 (25%) 7 (30%) 5 (19%) .36
Currently taking anastrozole 27 (52%) 13 (54%) 14 (50%) .76
Currently taking Letrozole 30 (53%) 16 (53%) 14 (52%) .91
Hysterectomy 31 (50%) 14 (44%) 17 (57%) .31
Taking vitamin D supplement 47 (80%) 28 (90%) 19 (68%) .03
Forgetting/choosing not to take AI .04
Never forget 44 (79%) 25 (89%) 19 (68%)
Forget once a week 11 (20%) 2 (7%) 9 (32%)
Forget twice a week 1 (2%) 1 (4%) 0 (0%)
Never choose not to take AI 54 (100%) 27 (100%) 27 (100%) 1.0
Self-reported joint pain
WOMAC, paina 6.96 3.4 7.26 3.6 6.76 3.1 .50
WOMAC, stiffnessa 4.06 1.6 4.46 1.9 3.76 1.3 .07
WOMAC, difficultya 22.26 10.6 24.66 10.5 20.06 10.4 .11
WOMAC, total scorea 336 14.4 36.26 14.9 30.56 13.8 .17
Pain, VASa 5.26 2.3 5.36 2.5 5.16 2.0 .79
Fatigue, VASa 4.36 2.8 4.26 3.1 4.36 2.5 .94
Stiffness, VASa 4.96 2.4 4.86 2.5 4.96 2.4 .89
Pain points, totala 4.56 2.0 4.76 2.1 4.36 1.9 .45
Psychosocial measures
Pain ASEb 6.36 2.3 5.76 2.4 6.86 2.1 .06
Symptom ASEb 6.76 2.2 6.26 2.4 7.16 1.7 .10
OEEc 2.26 0.6 2.16 0.7 2.26 0.6 .73
SEPAd 2.66 0.9 2.56 0.8 2.66 0.9 .74
FACT-G, physicale 20.96 4.7 20.86 4.7 21.16 4.9 .81
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potential study participants. Of these patients, 54 were elimi-
nated from further consideration based on oncology provider
concerns—disease advancement, other medical complexities,
or psychosocial issues on the day they were in clinic). Of the
patients approached by research staff, 18 declined to be con-
sidered for the study. Of the remaining 344 patients screened
in person by research staff, 266 (77%) were determined ineli-
gible for reasons of low/no pain and/or engagement in high lev-
els of physical activity. This left 78 patients who were
consented into the study, of which 62 (79% of 78) completed
the baseline questionnaire—11 patients were no longer inter-
ested in the study, 4 had psychosocial reasons (such as losing a
job or taking care of an ailing husband), and 1 had cancer pro-
gression. Thirty-one patients who completed the baseline ques-
tionnaire were randomized to Intervention and 31 patients to
WLC. Nine participants did not complete the 6-week question-
naire, leaving 53 (85% of 62) for the ITT analysis—24 Interven-
tion and 29 WLC. At 6-months postintervention, 41 (77% of 53)
completed the 6-months questionnaire. No adverse events
related to the intervention were reported.
Study Participants
An overview of baseline characteristics of Intervention and WLC
groups is presented in Table 2. Self-assessed general health was
rated very good/excellent by 30% of participants, while the
remainder rated their general health as fair, good, and between
fair and good. Participants averaged just under 3 years since
breast cancer diagnosis. Average amount of time on AI was 1.7
years (SD 1.43), ranging from .17 to 7 years. Seventy-nine per-
cent of participants reported “never” forgetting to take their AI
therapy, 20% reported forgetting to take their AI about once a
week, and 2% reported forgetting to take their AI twice a week.
At baseline, significantly more Intervention participants than
WLC participants had ever taken tamoxifen (p5 .05), taken vita-
min D supplement (p5 .03), and never forgot to take their
AI (p5 .4).
At baseline,WOMAC scores (higher scores signifying greater
pain) were moderate for Pain (6.9 on a scale of 0–20), mid-
range for Stiffness (4.0 on a scale of 0–8), and moderate for Dif-
ficulty with Activities of Daily Living (22.2 on a scale of 0–68).
Visual Analog Scales (range 0–10) were in the mid-range for
Pain (5.2), Stiffness (4.9), and Fatigue (4.3). Mean number of
pain points (identified on a graphic of a human) was 4.5 out of
10. Overall psychosocial quality of life as measured by FACT-G
subscales (scale of 0–28, with higher scores signifying higher
quality of life) was moderately high: Physical Well-Being (20.9),
Social/Family Well-Being (21.2), Functional Well-Being (18.6),
and Emotional Well-Being (18.9). Perceived helplessness in cop-
ing with joint symptoms (RAI score, range 1–5, with higher
scores indicating greater perceived helplessness) was moderate
(2.3). Efficacy for self-management of arthritis symptoms (range
1–10, with higher scores signifying higher self-efficacy) was
moderately high for ASE Pain (6.3) and ASE Symptoms (6.7).
Outcome Expectations from Exercise (range 1–5, with lower
scores signifying higher expectations) were positive (2.2), and
Self-Efficacy for Physical Activity (range 1–5, with higher scores
signifying higher confidence in being physically active) were
mid-range (2.6). Average minutes walking per week was 35.5.
Intervention Impact at 6 Weeks
A summary of the mean change scores for Intervention
and WLC groups between baseline and end-of-
intervention (6 weeks) is presented in Table 3, adjusted
for baseline age, BMI, race, education, and breast cancer
stage. Measures indicating significant improvement in the
Intervention group included increased walking minutes
per week (p< .01) and improved WOMAC Stiffness core
(p< .05), WOMAC Difficulty with Activities of Daily Living/
Function (p< .01), WOMAC Total score (p< .01), and RAI
perceived helplessness score (p< .01). Cohen’s d effect
sizes were large for walking minutes/week (d5 1.17)
and medium or approaching medium for WOMAC Stiff-
ness (d5 0.45), WOMAC Difficulty/Function (d5 0.58),
WOMAC Total (d5 0.53), and RAI Score (d5 0.44). When
the WLC group completed the walking intervention (after
their wait period, at weeks 7 through 12), the beneficial
effects of walking were similar to those observed in
the Intervention group (weeks 1 through 6; data not
presented).
Table 2. (continued)
Characteristic
Total
n (%)
Intervention
n (%)
Wait List Control
n (%) p valuea
FACT-G, social/familye 21.26 5.9 21.06 6.1 21.56 5.7 .74
FACT-G, functionale 18.66 5.6 17.36 6.7 19.96 3.8 .07
FACT-G, emotionale 18.96 4.7 18.46 5.0 19.36 4.3 .46
RAI scoref 2.36 0.9 2.46 1.0 2.26 0.9 .39
Walking
Walking time, min/wk 35.56 50.4 32.26 49.7 39.06 51.7 .61
Result of Student’s t test (continuous variables) or chi-square test (categorical variables) for determining if the Intervention and Wait List Control
means are significantly different.
aHigher scores indicate greater symptom severity.
bLower scores indicate lower self-efficacy in managing pain and symptoms.
cHigher scores indicate negative outcome expectations from exercise.
dHigher scores indicate higher confidence in being physically active.
eLower scores indicate worse well-being.
fHigher scores indicate greater perceived helplessness.
Abbreviatons: ASE, arthritis self-efficacy scale; FACT-G, functional assessment of cancer therapy-general; OEE, outcome expectations from exercise;
RAI, rheumatology attitudes index; SEPA, self-efficacy for physical activity; VAS, visual analog scale; WOMAC, Western Ontario and McMaster Uni-
versities osteoarthritis index.
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Table 3. Covariate-adjusteda means (SD) for baseline and 6-week follow-up measures—postwalking for Intervention group,
no walking for Wait List Control group
Outcome Time point Intervention Wait List Control Effect size
Walking
Walking time, min/wk Baseline mean (SD) 32.49 (55.12) 39.38 (55.02)
6-week mean (SD) 108.7 (55.32) 49.89 (54.92)
Change (95% CI) 76.22 (51.33, 101.1)
c 10.52 (–12.08, 33.12) 1.17 (0.54, 1.81)
Self-reported arthritis symptoms
WOMAC, paind Baseline mean (SD) 7.22 (3.34) 6.57 (3.32)
6-week mean (SD) 6.82 (3.42) 6.65 (3.32)
Change (95% CI) 20.4 (–1.91, 1.1) 0.08 (–1.31, 1.46) 0.14 (–0.41, 0.70)
WOMAC, stiffnessd Baseline mean (SD) 4.43 (1.66) 3.66 (1.65)
6-week mean (SD) 3.49 (1.72) 3.48 (1.65)
Change (95% CI) –0.94 (–1.78, 20.11)
b
20.18 (–0.94, 0.57) 0.45 (–0.11, 1.02)
WOMAC, difficultyd Baseline mean (SD) 24.39 (10.42) 19.84 (10.43)
6-week mean (SD) 17.69 (10.6) 19.35 (10.28)
Change (95% CI) –6.69 (–11.35, 22.04)
c
20.49 (–4.51, 3.53) 0.58 (–0.05, 1.22)
WOMAC, total scored Baseline mean (SD) 35.99 (14.11) 30.41 (14.25)
6-week mean (SD) 27.24 (14.55) 29.29 (14)
Change (95% CI) –8.75 (–15.01, 22.5)
c
21.13 (–6.44, 4.19) 0.53 (–0.10, 1.16)
Pain, VASd Baseline mean (SD) 5.22 (2.43) 4.95 (2.43)
6-week mean (SD) 4.47 (2.53) 4.82 (2.44)
Change (95% CI) 20.75 (–1.93, 0.44) 20.12 (–1.24, 0.99) 0.25 (–0.37, 0.87)
Fatigue, VASd Baseline mean (SD) 4.2 (2.81) 4.32 (2.82)
6-week mean (SD) 4.83 (2.87) 4.77 (2.82)
Change (95% CI) 0.63 (–0.56, 1.82) 0.45 (–0.63, 1.53) 0.06 (–0.53, 0.65)
Stiffness, VASd Baseline mean (SD) 4.76 (2.48) 4.99 (2.49)
6-week mean (SD) 4.52 (2.58) 5.17 (2.48)
Change (95% CI) 20.24 (–1.53, 1.05) 0.18 (–1.02, 1.38) 0.17 (–0.45, 0.78)
Psychosocial measures
Pain ASEd Baseline mean (SD) 5.73 (2.13) 6.87 (2.13)
6-week mean (SD) 5.26 (2.11) 6.98 (2.11)
Change (95% CI) 20.46 (–1.32, 0.4) 0.12 (–0.67, 0.91) 0.27 (–0.29, 0.83)
Symptom ASEd Baseline mean (SD) 6.25 (2.09) 7.17 (2.07)
6-week mean (SD) 5.71 (2.08) 7.15 (2.07)
Change (95% CI) 20.53 (–1.43, 0.36) 20.02 (–0.86, 0.82) 0.24 (–0.31, 0.80)
OEEe Baseline mean (SD) 2.09 (0.61) 2.2 (0.61)
6-week mean (SD) 2.13 (0.59) 2.26 (0.6)
Change (95% CI) 0.04 (–0.18, 0.26) 0.06 (–0.15, 0.26) 0.03 (–0.53, 0.59)
SEPAf Baseline mean (SD) 2.57 (0.82) 2.56 (0.82)
6-week mean (SD) 2.88 (0.83) 2.73 (0.82)
(continued)
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Six-Months Follow-Up
A summary of findings at 6-months follow-up is presented in
Table 4. Total walking minutes per week decreased significantly
from postintervention to 6-months follow-up (p< .01), illus-
trating the challenge of sustaining behavioral interventions in
the absence of continued active intervention. Rheumatology
Attitudes Index perceived helplessness scores returned to base-
line values (p< .01). However, improvements seen in WOMAC
Stiffness, Difficulty/Function, and Total scores were largely
maintained at 6 months, suggesting longer-lasting impact.
Satisfaction with WWE-BC
In response to the question “I benefitted from doing the WWE
program,” all who responded (n5 36) said they agreed or
strongly agreed with this statement, including participants in
WLC after they had completed the walking intervention. There
was similar agreement/strong agreement (100%) with the
statement “The WWE program motivated me to become more
physically active” (n5 37) and with the statement “I would rec-
ommend the WWE program to a friend or family member”
(97%). Regarding the statement “I think the WWE program is
an appropriate amount of time (6 weeks) to see benefits from
the program”, 83% agreed/strongly agreed while 17% dis-
agreed or strongly disagreed (n5 31). Eighty-three percent
thought the WWE workbook was very helpful or somewhat
helpful with reaching their walking goals (n5 30).
DISCUSSION
We conducted a “proof of concept” study to evaluate the impact
of an evidence-based self-directed walking program on joint
symptoms in breast cancer survivors experiencing moderate to
severe AIAA. Study participants significantly increased their
walking minutes per week during the 6-week walking period,
and walking was associated with significant improvements in
Table 3. (continued)
Outcome Time point Intervention Wait List Control Effect size
Change (95% CI) 0.3 (–0.09, 0.7) 0.17 (–0.19, 0.53) 0.16 (–0.41, 0.74)
FACT-G, physical well-beingg Baseline mean (SD) 20.9 (4.7) 20.73 (4.67)
6-week mean (SD) 21.26 (4.62) 21.06 (4.63)
Change (95% CI) 0.36 (–1.5, 2.22) 0.33 (–1.4, 2.06) 0.01 (–0.55, 0.56)
FACT-G, social/family well-beingg Baseline mean (SD) 21.14 (5.58) 21.48 (5.54)
6-week mean (SD) 20.64 (5.28) 21.89 (5.45)
Change (95% CI) 20.51 (–2.25, 1.24) 0.41 (–1.2, 2.02) 0.16 (–0.39, 0.72)
FACT-G, functional well-beingg Baseline mean (SD) 17.55 (5.51) 19.74 (5.47)
6-week mean (SD) 18.42 (5.13) 18.98 (5.37)
Change (95% CI) 0.87 (–0.65, 2.39) 20.76 (–2.15, 0.64) 0.29 (–0.27, 0.85)
FACT-G, emotional well-beingg Baseline mean (SD) 18.84 (4.21) 19.07 (4.18)
6-week mean (SD) 18.67 (4.05) 19.11 (4.14)
Change (95% CI) 20.17 (–1.72, 1.38) 0.05 (–1.36, 1.46) 0.05 (–0.51, 0.61)
FACT-G total scoreg Baseline mean (SD) 78.42 (15.34) 80.95 (15.24)
6-week mean (SD) 79.9 (14.36) 81.02 (15)
Change (95% CI) 1.48 (–3.32, 6.27) 0.07 (–4.28, 4.42) 0.09 (–0.47, 0.65)
RAI scoreh Baseline mean (SD) 2.34 (0.94) 2.16 (0.93)
6-week mean (SD) 1.92 (0.87) 2.15 (0.91)
Change (95% CI) –0.43 (–0.68, 20.17)
c
20.01 (–0.25, 0.23) 0.44 (–0.12, 1.00)
aAdjusted for baseline age, BMI, race, education, and breast cancer stage.
b
p< .05.
c
p< .01.
dHigher scores indicate greater symptom severity.
Lower scores indicate lower self-efficacy in managing pain and symptoms.
eHigher scores indicate negative outcome expectations from exercise.
fHigher scores indicate higher confidence in being physically active.
gLower scores indicate worse well-being.
hHigher scores indicate greater perceived helplessness.
Abbreviations: ASE, arthritis self-efficacy scale; CI, confidence interval; FACT-G, functional assessment of cancer therapy-general; OEE, outcome
expectations from exercise; RAI, rheumatology attitudes index; SEPA, self-efficacy for physical activity; SD, standard deviation; VAS, visual analog
scale; WOMAC,Western Ontario and McMaster Universities osteoarthritis index.
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WOMAC Stiffness, Difficulty with Activities of Daily Living/
Function scales,WOMAC Total score, and perceived helplessness
in managing their joint symptoms (RAI).When the 10 study par-
ticipants with stage IV breast cancer were excluded from the
analysis, the FACT-G measures showed even greater improve-
ment for Intervention compared withWLC postintervention.
These findings are promising and warrant further explora-
tion in a large-sample trial. Our findings corroborate those
reported in an earlier pilot study of WWE-BC that assessed the
feasibility of the home-based walking program in breast cancer
survivors age 65 and older, which suggested intervention bene-
fits for reducing joint stiffness [8]. At 6-months follow-up, the
minutes/week that participants walked declined to preinterven-
tion levels and a return to baseline values was seen for most
psychosocial and efficacy measures. However, it is notable
that WOMAC Stiffness, Difficulty/Function, and Total scores
remained at the improved levels seen immediately
postintervention.
Our findings join a small but growing number of studies eval-
uating the potential benefits of physical activity in managing
AIAA. Of these studies, the largest to date, by Irwin and col-
leagues, was a randomized controlled trial in breast cancer survi-
vors reporting less than 90 minutes a week of aerobic exercise,
no strength training, and scoring 3 for worst joint pain (scale
0–10) [23, 24]. Participants in that study (n5 121) were
randomized to usual care or an exercise intervention that
included twice-weekly supervised resistance training and home-
based aerobic exercise, with increasing intensity over time. At
end of intervention (12 months), the intervention group
reported at 29% decrease in “worst” joint pain scores, while the
usual care group reported a 3% increase (p< .001). Similarly,
pain severity and pain interference scores declined significantly
in the intervention compared with usual care group (p< .001).
The authors did not find a dose-response effect of exercise;
more exercise was not associated with greater improvement in
joint symptoms. Other small scale studies of exercise to reduce
AIAA have explored aquatic exercise [25], Nordic walking [26],
and an 8-week home-based aerobic and resistance exercise pro-
gram [27], and all have reported promising benefits. Recent
meta-analyses of AIAA management interventions rated the
Table 4. Covariate-adjusteda means (SD) for postintervention to 6-month follow-up measures to assess whether outcomes
seen postintervention were maintained at 6 months
Outcome
Mean (SD)
at baseline
Mean (SD) at
postintervention
Mean (SD)
at 6 months
Mean change (95% CI)
from postintervention
to 6 months
Walking
Walking time, min/wk 36.29 (59.96) 101.14 (68.41) 66.15 (85.5) 234.99 (–58.86, 211.12)
b
Self-reported arthritis symptoms
WOMAC, painc 6.92 (3.51) 6.09 (3.81) 6.76 (4.67) 0.67 (20.45, 1.78)
WOMAC, stiffnessc 4.07 (1.76) 3.12 (1.91) 3.27 (2.4) 0.14 (20.47, 0.75)
WOMAC, difficultyc 22.07 (10.57) 17.71 (11.63) 18.23 (14.61) 0.52 (23.46, 4.5)
WOMAC, total scorec 33.21 (14.86) 26.63 (15.89) 27.56 (19.81) 0.92 (24.43, 6.28)
Pain, VASc 5.14 (2.58) 4.33 (2.83) 4.49 (3.54) 0.16 (20.86, 1.18)
Fatigue, VASc 4.32 (3.02) 4.4 (3.35) 4.09 (3.88) 20.31 (21.28, 0.65)
Stiffness, VASc 4.85 (2.48) 4.33 (2.68) 4.32 (3.42) 20.01 (20.98, 0.96)
Psychosocial measures
Pain ASEd 6.31 (2.24) 5.99 (2.49) 6.53 (3) 0.53 (20.19, 1.26)
Symptom ASEd 6.72 (2.17) 6.28 (2.42) 6.64 (3.24) 0.36 (20.52, 1.24)
OEEe 2.15 (0.65) 2.15 (0.74) 2.08 (0.91) 20.07 (20.31, 0.16)
SEPAf 2.55 (0.89) 2.85 (0.88) 2.9 (1.19) 0.04 (20.26, 0.34)
FACT-G, physicalg 20.82 (4.87) 21.71 (5.42) 21.06 (6.46) 20.65 (22.18, 0.87)
FACT-G, social/familyg 21.23 (5.83) 20.84 (6.34) 20.86 (7.35) 0.01 (21.58, 1.61)
FACT-G, functionalg 18.59 (5.69) 18.96 (6.21) 19.42 (7.22) 0.46 (21.12, 2.04)
FACT-G, emotionalg 18.89 (4.43) 18.55 (5) 18.58 (5.99) 0.03 (21.45, 1.51)
FACT-G total scoreg 79.49 (16.17) 80.49 (17.79) 79.66 (20.66) 20.82 (25.48, 3.83)
RAI scoreh 2.26 (0.96) 1.95 (1.07) 2.29 (1.14) 0.34 (0.11, 0.56)b
aAdjusted for baseline age, BMI, race, education, and breast cancer stage.
b
p< .01.
cHigher scores indicate greater symptom severity.
dLower scores indicate lower self-efficacy in managing pain and symptoms.
eHigher scores indicate negative outcome expectations from exercise.
fHigher scores indicate higher confidence in being physically active.
gLower scores indicate worse well-being.
hHigher scores indicate greater perceived helplessness.
Abbreviations: ASE, arthritis self-efficacy scale; CI, confidence interval; FACT-G, functional assessment of cancer therapy-general; OEE, outcome
expectations from exercise; RAI, rheumatology attitudes index; SD, standard deviation; SEPA, self-efficacy for physical activity; VAS, visual analog
scale; WOMAC,Western Ontario and McMaster Universities osteoarthritis index.
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overall evidence regarding exercise to reduce AIAA as moderate
and that further studies are needed [6, 28].
A strength of our study is that, similar to the Irwin study [23,
24], it is focused specifically on women experiencing moderate
to severe AIAA. This subset of breast cancer survivors is in great-
est need of effective ways to manage their joint symptoms,
because they are at risk of suboptimal adherence and discontin-
uation and poor quality of life. A further strength is that we used
a simple, scalable intervention that is evidence-based in reduc-
ing arthritis and joint symptoms [7] and offers web-based sup-
port for adults wanting to pursue a more active lifestyle (http://
www.arthritis.org/living-with-arthritis/tools-resources/walk-with-
ease/) [13]. Our findings suggest that almost any level of
increased physical activity may reduce AIAA and that home-
based physical activity can be done at a time, place, and pace to
accommodate the wide variety of lifestyles of breast cancer sur-
vivors. And, while our study was focused on women with moder-
ate to severe joint symptoms, survivors experiencing milder AIAA
symptoms may experience similar benefits.
Our study has some limitations. We have noted earlier that
there was some unintentional mis-randomization; however, sen-
sitivity analysis did not change the overall results of our study.
The findings were the same regardless of whether the analysis
was according to original random assignment or mis-
randomization. Our final sample is over-represented with
women with more than a high school education; however, the
proportion of nonwhite women (28% Intervention and 23%
WLC) is representative of the racial mix of the state where the
study was conducted. Recruitment was challenging in light of
the dual requirements for moderate to severe joint symptoms
and below guideline recommended levels of physical activity. As
we screened survivors for study eligibility, many women
reported high levels of exercise despite substantial joint pain.
We did not collect information on the type or intensity of exer-
cise that these women engaged in, only the number of minutes
per week. As in all behavioral intervention studies, there is
always the self-selection bias of women who are willing and able
to participate in this type of study, which affects generalizability
to the general population of female breast cancer survivors.
A second limitation was the shortness of our intervention
period—6weeks, as tested in the original WWE study [7]; a lon-
ger intervention period may have produced stronger and more
lasting benefits for reducing joint symptoms and deserves fur-
ther investigation in a large sample trial. A future study might
also include intermittent contact with study participants to
encourage their engagement in walking, such as contacts via
telephone, text messages, or email. Further, although we
screened for new or recently-intensified joint symptoms, we
cannot rule out the possibility that some of the joint symptom
improvements were at least partially for arthritis pain and stiff-
ness, which are common in postmenopausal women.
CONCLUSION
Further studies are warranted; however, the combined evi-
dence of diverse studies cited above suggests that physical
activity can be offered to women on AI therapy as a safe alter-
native or adjunct to medications for the management of AIAA.
Guidelines in general recommend 150 minutes a week for
adults diagnosed with cancer [12], and this level of physical
activity could be an appropriate target for breast cancer survi-
vors seeking to manage their AIAA. Our interviews with breast
cancer survivors suggest that the message of exercise for the
management of AIAA would be well-received at the time AI
therapy is initiated, rather than waiting until joint symptoms
have started or intensified [10]. The breast cancer diagnosis can
present a “teachable moment” where patient-oncology pro-
vider conversations about physical activity can focus on physical
well-being and mental health as well as the potential for symp-
tom self-management.
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